Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaap Verweij

Showing results (111-120 of 234) with videos related to

Pageof 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obeseAlex Sparreboom, Antonio C Wolff, Ron H J Mathijssen, et al.
Clinical Pharmacology and Therapeutics|December 14, 2004
Mechanism-based models for topotecan-induced neutropeniaFrédéric Léger, Walter J Loos, Roland Bugat, et al.
Clinical Pharmacology and Therapeutics|July 2, 2004
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotypeAlex Sparreboom, Hans Gelderblom, Sharon Marsh, et al.
European Journal of Cancer (Oxford, England : 1990)|December 20, 2008
Individual patient data analysis to assess modifications to the RECIST criteriaJan Bogaerts, Robert Ford, Dan Sargent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusionsHans Gelderblom, Klaus Mross, Albert J ten Tije, et al.
Journal of the National Cancer Institute|December 19, 2002
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001Sharyn D Baker, Jaap Verweij, Eric K Rowinsky, et al.
The Oncologist|September 4, 2007
Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?Ron H J Mathijssen, Floris A de Jong, Walter J Loos, et al.
Journal of Clinical Pharmacology|August 3, 2004
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38Luca Paoluzzi, Arun S Singh, Douglas K Price, et al.
Japanese Journal of Cancer Research : Gann|January 23, 2002
O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivativesRyo Okamoto, Hiroshi Takano, Tatsunori Okamura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2003
Irinotecan pathway genotype analysis to predict pharmacokineticsRon H J Mathijssen, Sharon Marsh, Mats O Karlsson, et al.
Pageof 24

Showing results (111-120 of 234) with videos related to

Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obeseAlex Sparreboom, Antonio C Wolff, Ron H J Mathijssen, et al.
Clinical Pharmacology and Therapeutics|December 14, 2004
Mechanism-based models for topotecan-induced neutropeniaFrédéric Léger, Walter J Loos, Roland Bugat, et al.
Clinical Pharmacology and Therapeutics|July 2, 2004
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotypeAlex Sparreboom, Hans Gelderblom, Sharon Marsh, et al.
European Journal of Cancer (Oxford, England : 1990)|December 20, 2008
Individual patient data analysis to assess modifications to the RECIST criteriaJan Bogaerts, Robert Ford, Dan Sargent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusionsHans Gelderblom, Klaus Mross, Albert J ten Tije, et al.
Journal of the National Cancer Institute|December 19, 2002
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001Sharyn D Baker, Jaap Verweij, Eric K Rowinsky, et al.
The Oncologist|September 4, 2007
Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?Ron H J Mathijssen, Floris A de Jong, Walter J Loos, et al.
Journal of Clinical Pharmacology|August 3, 2004
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38Luca Paoluzzi, Arun S Singh, Douglas K Price, et al.
Japanese Journal of Cancer Research : Gann|January 23, 2002
O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivativesRyo Okamoto, Hiroshi Takano, Tatsunori Okamura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2003
Irinotecan pathway genotype analysis to predict pharmacokineticsRon H J Mathijssen, Sharon Marsh, Mats O Karlsson, et al.
Pageof 24